Business Wire

Takeda Reports First Half FY2017 Results

Jaa

Takeda Pharmaceutical Company Limited (TOKYO:4502):

Underlying Revenue growth of 6.7% led by Takeda's Growth Drivers

  • Underlying Revenue grew +6.7% with solid performances across all regions (U.S. +16.7%, Japan +0.3%, Europe & Canada +4.2%, Emerging Markets +3.4%). Takeda's Growth Drivers (GI, Oncology, CNS and Emerging Markets) maintained strong momentum to deliver growth of +14.9%.
    • GI (Gastroenterology) +24.8% fueled by market share growth of ENTYVIO® and TAKECAB®.
    • Oncology +13.2% driven by the expansion of NINLARO® and ADCETRIS®, and the addition of revenue from ICLUSIG® and ALUNBRIGTM.
    • CNS +26.7% with TRINTELLIX® growing +58.7% in the U.S.
    • Emerging Markets +3.4% with strong double-digit growth in the key markets of Russia and Brazil offsetting a temporary decline in China.
  • Reported revenue grew +3.6%, with the positive contribution from Takeda's Growth Drivers and favorable currency impact (+2.4pp) more than offsetting the negative impact of divestitures (-5.5pp).

Double-digit EPS growth reflecting strong revenue growth and progress of Global Opex Initiative

  • Underlying Core Earnings grew +44.4%, reflecting strong revenue growth and margin step up of 5.0pp (+2.7pp gross margin; +2.3pp from OPEX margin). First half earnings growth included some timing benefits.
  • Reported operating profit was up +44.6%, driven mainly by strong Core Earnings growth. The first half result includes one-time gains of 136.8 billion yen, including the sale of shares held in Wako Pure Chemical Ltd., the sale of real estate, and the transfer of additional long-listed products to Teva Takeda Yakuhin Ltd.
  • Underlying Core EPS was up +29.9%, and reported EPS increased +39.2% to 221 yen per share.

Net leverage improved due to steady progress on cash flow

  • Year-to-date Operating Free Cash Flow increased +12.4% to 84.6 billion yen, and the disposal of non-core assets generated an additional 131 billion yen of cash.
  • Net Debt / EBITDA dropped to 2.0x from 2.7x in March 2017.

Christophe Weber, Chief Executive Officer of Takeda, commented:
"Our Growth Drivers continued to deliver robust double-digit revenue growth, which together with our cost management initiatives led to a significant margin expansion. Furthermore, the ARIAD acquisition is delivering ahead of expectations, and the R&D transformation is well advanced. Although we expect headwinds in the second half of the year, we are still confident to raise our outlook for the full year as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability."

 

Reported Results for H1 (April - September) FY2017

(billion yen)   FY2016 H1   FY2017 H1   Growth
Reported   Underlying 2
Revenue 850.8 881.4 +3.6% +6.7%
Core Earnings1 131.0 187.1 +42.8% +44.4%
Operating Profit 162.1 234.3 +44.6% -
Net Profit3 124.3 172.8 +39.0% -
EPS 159 yen 221 yen +39.2% -
Core EPS   139 yen   181 yen   +30.0%   +29.9%

1

  Core Earnings is calculated by deducting SG&A expenses and R&D expenses from reported Gross Profit. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.

2

Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures.

3

Attributable to the owners of the company.
 

Takeda raises its full-year outlook despite second half headwinds

  • Increasing Management Guidance and Reported Forecast to reflect favorable year-to-date results. The Reported Forecast also benefits from lower impairment and restructuring expenses compared to the previous forecast.
  • The majority of one-time gains were booked in the first half, and the majority of one-time expenses will be booked in the second half. The outlook also assumes loss of exclusivity of Velcade.
  • Velcade estimates are based on the possible entry of 2 or 3 bortezomib-containing products in the U.S. from November 2017. Depending on various factors there may be an additional opportunity up to 30 billion yen, which will be partly reinvested in the business.
 

FY2017 Management Guidance: Raising underlying profit guidance and Core Earnings margin expansion now expected at ~200bps

    Previous Guidance (growth %)
(May 10, 2017)
  Revised Guidance (growth %)
(Nov 1, 2017)
Underlying Revenue Low single digit Low single digit
Underlying Core Earnings Mid-to-high teen High teen
Underlying Core EPS Low-to-mid teen Mid teen
Annual Dividend per Share   180 yen   180 yen
 

FY2017 Reported Forecast: Increasing Reported Revenue and Earnings forecasts, with EPS increased by 10% to 195 yen per share

(billion yen)   Previous Forecast
(May 10, 2017)
  Revised Forecast

(Nov 1, 2017)

  vs. FY2016
Revenue 1,680.0 1,720.0 -0.7%
Core Earnings 257.5 267.5 +9.1%
Operating Profit 180.0 200.0 +28.3%
Net Profit 138.0 152.0 +32.2%
EPS 177 yen 195 yen +32.3%
Exchange Rate (annual average)   1 US$=110 yen

1 euro=120 yen

  1 US$=112 yen

1 euro=129 yen

   
 

For more details on Takeda's FY2017 first half results and other financial information, please visit https://www.takeda.com/investors/reports/

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

Contact information

Investor Relations
Takeda Pharmaceutical Company Limited
+81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Takeda Pharmaceutical Company Limited
Tsuyoshi Tada, +81 (0)3-3278-2417
tsuyoshi.tada@takeda.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

QNB Group: Financial Results for the Year Ended 31 December 201716.1.2018 16:26Tiedote

QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the year ended 31 December 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116006048/en/ QNB Group HQ Building in Doha (Photo: AETOSWire) For the year ended 2017, Net Profit reached QAR13.1 billion (USD3.6 billion), up by 6% compared to last year. Total assets increased by 13% from December 2016 to reach QAR811 billion (USD223 billion), the highest ever achieved by the Group. The Board of Directors have recommended to the General Assembly for the distribution of a cash dividend of 60% of the nominal share value (QAR 6.0 per share). The financial results for 2017 along with the profit distribution are subject to Qatar Central Bank (QCB) approval. Key driver of total assets growth was from loans and advances which grew by 12% to reach QAR584 billion (USD161 billion). Also QNB Group increased customer deposi

H.I.G. Capital Acquires Majority Stake in Beinbauer Group16.1.2018 15:35Tiedote

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Beinbauer Group (“Beinbauer”). Beinbauer, headquartered in Büchlberg near Passau, Germany, is a leading provider of complex machined metal parts (iron, steel, aluminium) for the European on- and off-highway commercial vehicle industry (OEMs and other tier-1 suppliers). Beinbauer’s core competencies are the machining of components and assemblies in state-of-the-art production processes as well as building and managing complex supplier networks, offering its customers all-in-one solutions for axle, frame, chassis and engine parts from a single source. Beinbauer operates four production sites in Germany and has approximately 700 employees. In 2017, Beinbauer generated revenues of more than €200 million. The Beinbauer management team, headed by Tobias Lührig and Patric Meeth, will c

Bidgely Closes $27M Series C to Grow Artificial Intelligence Solution for Utilities and Energy Retailers16.1.2018 14:00Tiedote

U.S.-based Bidgely announced today the closing of a $27 million Series C round of financing, marking the largest round of investment to date for any energy disaggregation technology. Georgian Partners, an investment fund known for its focus on high-growth enterprise software companies that use applied artificial intelligence to disrupt markets, led the oversubscribed round. Returning investors include Khosla Ventures, E.ON, and innogy. Constellation Technology Ventures, the venture capital arm of Exelon Corporation, is also expected to return. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005615/en/ Bidgely Energy Usage Itemisation (Photo: Business Wire) “We invest in high-growth SaaS companies that are applying AI to solve real-world business problems,” said Simon Chong, Managing Partner at Georgian Partners. “Bidgely is using machine learning to fundamentally reinvent customer engagement with utilities and enable a n

Glennmont Seeks More Than 500MW of Investment Opportunities in Clean Energy Infrastructure Assets with Expanded Investment Capacity16.1.2018 13:19Tiedote

Glennmont Partners has expanded its investment capacity in the clean energy infrastructure space and now has three funds under management – these are Fund I (2010) and Fund II (2013), which are fully invested, and now a new third Fund (2017). Opportunities are being sought for a portfolio of clean energy infrastructure projects in Europe. Glennmont is one of Europe’s largest investors focusing exclusively on investment in clean energy infrastructure. This announcement follows the successful refinancing of Glennmont’s 245MW Italian wind portfolio in October and the refinancing of the Sleaford straw-fired biomass plant in September - amounting to around €340m of capital raised over the course of 2017. Glennmont’s strategy remains consistent with its past experiences: it seeks to invest in solar PV, offshore and onshore wind, bioenergy and small-scale hydro across the EEA; it will target to-be-built and recently operational assets with stable, predictable cash yields underpinned by regula

Breed Reply Portfolio of IoT Start-Ups Raise in Excess of $50 Million in Series A Funding in 201716.1.2018 13:00Tiedote

Breed Reply, a leading operational investor in early-stage internet of things (IoT) businesses, saw one third of its 18-strong portfolio of investee companies, complete series A funding rounds in 2017. In total, six companies raised in excess of $50 million during the year with funds coming from notable investors including Accel, Aviva Ventures, Finance Wales, Intu and MunichRE. More companies in the growing portfolio are expected to be ready for Series A investment in 2018. The successful companies span a broad range of IoT sectors: Callsign (Cyber Security); Cocoon (Smart Home); enModus (Smart Building); Senseye (Industrial); WePredict (Big Data); and Zeetta Networks (Platforms). Helping start-ups prepare for future funding is a crucial part of Breed Reply’s commitment to companies when it invests. As an active operational investor, Breed Reply works closely with management to accelerate the company’s development to achieve Series A funding and beyond. The team has significant experi

MagicStay Raises 1.5 Million Euros to Accelerate Its Development16.1.2018 13:00Tiedote

The short-term rental start-up for business travelers MagicStay.com , has just finalized a new round of fundraising to continue its development. Just four years since its release, the rental platform already offers 150,000 apartments in 90 countries and has taken a leading position in the alternative accommodation industry. The fundraising totaling 1.5 million Euros was led by the start-up’s main shareholders (Michaël Benabou, Benoit Bassi, Patrick Lucas, Nicolas Quenedey or Charles Petruccelli, former CEO of American Express Global Business Travel...), as well as new investors, including Marc Frappier, Managing Partner of Eurazeo and Head of Eurazeo Capital, Thibault Basquin, Managing Director of Ardian, Nicolas Santi-Weil, CEO of AMI Paris... This round table will let the start-up accelerate its exclusive technological development for employees of large companies to book secure apartments as easily as hotel rooms, via either existing booking tools (Hotel Booking Tool, Self Booking To

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme